International Journal of Endocrinology and Metabolism

Published by: Kowsar
Crossmark

Cause-Specific Risk Factors of Death in Individuals with Diabetes: A Competing Risks Modeling

Marjan Mansourian 1 , Sahar Sadeghpour 1 , Ashraf Aminorroaya 2 , Masoud Amini 2 and Tohid Jafari-Koshki 3 , 4 , *
Authors Information
1 Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran
2 Isfahan Endocrine and Metabolism Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran
3 Medical Education Research Center, Health Management and Safety Promotion Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran
4 Department of Statistics and Epidemiology, Faculty of Health, Tabriz University of Medical Sciences, Tabriz, Iran
Article information
  • International Journal of Endocrinology and Metabolism: 17 (3); e69419
  • Published Online: June 3, 2019
  • Article Type: Research Article
  • Received: April 15, 2018
  • Revised: April 16, 2019
  • Accepted: May 18, 2019
  • DOI: 10.5812/ijem.69419

To Cite: Mansourian M , Sadeghpour S , Aminorroaya A, Amini M , Jafari-Koshki T. Cause-Specific Risk Factors of Death in Individuals with Diabetes: A Competing Risks Modeling, Int J Endocrinol Metab. Online ahead of Print ; 17(3):e69419. doi: 10.5812/ijem.69419.

Abstract
Copyright © 2019, International Journal of Endocrinology and Metabolism. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Jafari-Koshki T, Mansourian M, Hosseini SM, Amini M. Association of waist and hip circumference and waist-hip ratio with type 2 diabetes risk in first-degree relatives. J Diabetes Complications. 2016;30(6):1050-5. doi: 10.1016/j.jdiacomp.2016.05.003. [PubMed: 27311785].
  • 2. Baena-Diez JM, Penafiel J, Subirana I, Ramos R, Elosua R, Marin-Ibanez A, et al. Risk of cause-specific death in individuals with diabetes: A competing risks analysis. Diabetes Care. 2016;39(11):1987-95. doi: 10.2337/dc16-0614. [PubMed: 27493134].
  • 3. Yamagishi S. Cardiovascular disease in recent onset diabetes mellitus. J Cardiol. 2011;57(3):257-62. doi: 10.1016/j.jjcc.2011.01.011. [PubMed: 21367583].
  • 4. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-93. doi: 10.1056/NEJMoa021778. [PubMed: 12556541].
  • 5. Jafari-Koshki T, Hosseini SM, Arsang-Jang S, Amini M, Faghihimani E. Trends of diabetic nephropathy prevalence in Isfahan, Iran, during 1992-2010. J Res Med Sci. 2015;20(10):944-9. doi: 10.4103/1735-1995.172781. [PubMed: 26929758]. [PubMed Central: PMC4746867].
  • 6. Phipps MS, Jastreboff AM, Furie K, Kernan WN. The diagnosis and management of cerebrovascular disease in diabetes. Curr Diab Rep. 2012;12(3):314-23. doi: 10.1007/s11892-012-0271-x. [PubMed: 22492061].
  • 7. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: A consensus report. CA Cancer J Clin. 2010;60(4):207-21. doi: 10.3322/caac.20078.
  • 8. Griffiths RI, Danese MD, Gleeson ML, Valderas JM. Epidemiology and outcomes of previously undiagnosed diabetes in older women with breast cancer: An observational cohort study based on SEER-Medicare. BMC Cancer. 2012;12:613. doi: 10.1186/1471-2407-12-613. [PubMed: 23259613]. [PubMed Central: PMC3575284].
  • 9. Toriola AT, Stolzenberg-Solomon R, Dalidowitz L, Linehan D, Colditz G. Diabetes and pancreatic cancer survival: A prospective cohort-based study. Br J Cancer. 2014;111(1):181-5. doi: 10.1038/bjc.2014.224. [PubMed: 24786605]. [PubMed Central: PMC4090724].
  • 10. Gadepalli R, Dhawan B, Sreenivas V, Kapil A, Ammini AC, Chaudhry R. A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital. Diabetes Care. 2006;29(8):1727-32. doi: 10.2337/dc06-0116. [PubMed: 16873771].
  • 11. Liao EP. Management of type 2 diabetes: New and future developments in treatment. Am J Med. 2012;125(10):S2-3. doi: 10.1016/j.amjmed.2012.05.008. [PubMed: 22998892].
  • 12. Toya K, Babazono T, Murata H, Hanai K, Uchigata Y. Association of serum bilirubin levels with mortality in patients with diabetes initiating chronic hemodialysis: A competing risks analysis of a single-center cohort. Renal Replacement Therapy. 2016;2(1). doi: 10.1186/s41100-016-0065-8.
  • 13. Lim HJ, Zhang X, Dyck R, Osgood N. Methods of competing risks analysis of end-stage renal disease and mortality among people with diabetes. BMC Med Res Methodol. 2010;10:97. doi: 10.1186/1471-2288-10-97. [PubMed: 20964855]. [PubMed Central: PMC2988010].
  • 14. Forsblom C, Harjutsalo V, Thorn LM, Waden J, Tolonen N, Saraheimo M, et al. Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol. 2011;22(3):537-44. doi: 10.1681/ASN.2010020194. [PubMed: 21335512]. [PubMed Central: PMC3060447].
  • 15. Sadeghpour S, Faghihimani E, Hassanzadeh A, Amini M, Mansourian M. Predictors of all-cause and cardiovascular-specific mortality in type 2 diabetes: A competing risk modeling of an Iranian population. Adv Biomed Res. 2016;5:82. doi: 10.4103/2277-9175.182213. [PubMed: 27274497]. [PubMed Central: PMC4879860].
  • 16. Drake I, Gullberg B, Sonestedt E, Stocks T, Bjartell A, Wirfalt E, et al. Type 2 diabetes, adiposity and cancer morbidity and mortality risk taking into account competing risk of noncancer deaths in a prospective cohort setting. Int J Cancer. 2017;141(6):1170-80. doi: 10.1002/ijc.30824. [PubMed: 28593629]. [PubMed Central: PMC5575549].
  • 17. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206-52. doi: 10.1161/01.HYP.0000107251.49515.c2. [PubMed: 14656957].
  • 18. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. Blood Press. 2013;22(4):193-278. doi: 10.3109/08037051.2013.812549. [PubMed: 23777479].
  • 19. Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133(6):601-9. doi: 10.1161/CIRCULATIONAHA.115.017719. [PubMed: 26858290]. [PubMed Central: PMC4741409].
  • 20. Dignam JJ, Zhang Q, Kocherginsky M. The use and interpretation of competing risks regression models. Clin Cancer Res. 2012;18(8):2301-8. doi: 10.1158/1078-0432.CCR-11-2097. [PubMed: 22282466]. [PubMed Central: PMC3328633].
  • 21. Fine JP, Gray RJ. A proportional Hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509. doi: 10.1080/01621459.1999.10474144.
  • 22. Koller MT, Raatz H, Steyerberg EW, Wolbers M. Competing risks and the clinical community: Irrelevance or ignorance? Stat Med. 2012;31(11-12):1089-97. doi: 10.1002/sim.4384. [PubMed: 21953401]. [PubMed Central: PMC3575691].
  • 23. Gray RJ. A class of $k$-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-54. doi: 10.1214/aos/1176350951.
  • 24. Chen G, McAlister FA, Walker RL, Hemmelgarn BR, Campbell NR. Cardiovascular outcomes in framingham participants with diabetes: The importance of blood pressure. Hypertension. 2011;57(5):891-7. doi: 10.1161/HYPERTENSIONAHA.110.162446. [PubMed: 21403089]. [PubMed Central: PMC3785072].
  • 25. Lu WQ, Resnick HE, Jablonski KA, Jain AK, Jones KL, Robbins DC, et al. Effects of glycaemic control on cardiovascular disease in diabetic American Indians: The strong heart study. Diabet Med. 2004;21(4):311-7. doi: 10.1111/j.1464-5491.2004.01137.x. [PubMed: 15049931].
  • 26. Bonakdaran S, Ebrahimzadeh S, Noghabi SH. Cardiovascular disease and risk factors in patients with type 2 diabetes mellitus in Mashhad, Islamic Republic of Iran. East Mediterr Health J. 2011;17(9):640-6. doi: 10.26719/2011.17.9.640. [PubMed: 22259913].
  • 27. Sytkowski PA, Kannel WB, D'Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease. The framingham heart study. N Engl J Med. 1990;322(23):1635-41. doi: 10.1056/NEJM199006073222304. [PubMed: 2288563].
  • 28. Imperatore G, Cadwell BL, Geiss L, Saadinne JB, Williams DE, Ford ES, et al. Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: National Health and Nutrition Examination Surveys, 1971-2000. Am J Epidemiol. 2004;160(6):531-9. doi: 10.1093/aje/kwh232. [PubMed: 15353413].
  • 29. LaRosa JC. Understanding risk in hypercholesterolemia. Clin Cardiol. 2003;26(1 Suppl 1):I3-6. doi: 10.1002/clc.4960261303. [PubMed: 12539815].
  • 30. Jousilahti P, Vartiainen E, Pekkanen J, Tuomilehto J, Sundvall J, Puska P. Serum cholesterol distribution and coronary heart disease risk: Observations and predictions among middle-aged population in eastern Finland. Circulation. 1998;97(11):1087-94. [PubMed: 9531256].
  • 31. Cho E, Rimm EB, Stampfer MJ, Willett WC, Hu FB. The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol. 2002;40(5):954-60. doi: 10.1016/S0735-1097(02)02044-2. [PubMed: 12225722].
  • 32. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: Influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med. 2011;171(5):404-10. doi: 10.1001/archinternmed.2011.2. [PubMed: 21403036].
  • 33. Brun E, Nelson RG, Bennett PH, Imperatore G, Zoppini G, Verlato G, et al. Diabetes duration and cause-specific mortality in the Verona diabetes study. Diabetes Care. 2000;23(8):1119-23. doi: 10.2337/diacare.23.8.1119. [PubMed: 10937508].
  • 34. Boden-Albala B, Cammack S, Chong J, Wang C, Wright C, Rundek T, et al. Diabetes, fasting glucose levels, and risk of ischemic stroke and vascular events: Findings from the northern manhattan study (NOMAS). Diabetes Care. 2008;31(6):1132-7. doi: 10.2337/dc07-0797. [PubMed: 18339972].
  • 35. Lehto S, Ronnemaa T, Pyorala K, Laakso M. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke. 1996;27(1):63-8. doi: 10.1161/01.STR.27.1.63. [PubMed: 8553405].
  • 36. Janghorbani M, Hu FB, Willett WC, Li TY, Manson JE, Logroscino G, et al. Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes: The nurses' health study. Diabetes Care. 2007;30(7):1730-5. doi: 10.2337/dc06-2363. [PubMed: 17389335].
  • 37. Banerjee C, Moon YP, Paik MC, Rundek T, Mora-McLaughlin C, Vieira JR, et al. Duration of diabetes and risk of ischemic stroke: The northern manhattan Study. Stroke. 2012;43(5):1212-7. doi: 10.1161/STROKEAHA.111.641381. [PubMed: 22382158]. [PubMed Central: PMC3336044].
  • 38. Malek M, Aghili R, Emami Z, Khamseh ME. Risk of cancer in diabetes: The effect of metformin. ISRN Endocrinol. 2013;2013:636927. doi: 10.1155/2013/636927. [PubMed: 24224094]. [PubMed Central: PMC3800579].
  • 39. Vupputuri S, Nichols GA, Lau H, Joski P, Thorp ML. Risk of progression of nephropathy in a population-based sample with type 2 diabetes. Diabetes Res Clin Pract. 2011;91(2):246-52. doi: 10.1016/j.diabres.2010.11.022. [PubMed: 21156326].
  • 40. Saberi H, Mohammadtaghvaei N, Gulkho S, Bakhtiyari S, Mohammadi M, Hanachi P, et al. The ENPP1 K121Q polymorphism is not associated with type 2 diabetes and related metabolic traits in an Iranian population. Mol Cell Biochem. 2011;350(1-2):113-8. doi: 10.1007/s11010-010-0687-z. [PubMed: 21153685].
  • 41. Levin ME. Foot lesions in patients with diabetes mellitus. Endocrinol Metab Clin North Am. 1996;25(2):447-62. doi: 10.1016/s0889-8529(05)70333-9.
  • 42. Walters DP, Gatling W, Mullee MA, Hill RD. The distribution and severity of diabetic foot disease: A community study with comparison to a non-diabetic group. Diabet Med. 1992;9(4):354-8. doi: 10.1111/j.1464-5491.1992.tb01796.x. [PubMed: 1600707].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments